RC48 + sintilimab + XELOX

Based on the provided text, specific information about the complete combination therapy of RC48 + sintilimab + XELOX is not available in the search results. The text only provides details about the XELOX component. ## XELOX/CAPOX Regimen XELOX (also called CAPOX) is a chemotherapy regimen that combines oxaliplatin and capecitabine. It's used to treat various gastrointestinal cancers including colorectal, stomach, and esophageal cancers. XELOX consists of: - Oxaliplatin: Given as an intravenous infusion (130 mg/m²) on day 1 of a 3-week cycle - Capecitabine (Xeloda): Oral tablets (1,000 mg/m² twice daily) taken from day 1 (evening) to day 15 (morning) The treatment is typically administered in 3-week cycles, with oxaliplatin given on day 1 and capecitabine taken for 14 days followed by a 7-day rest period. ### Mechanism of Action These chemotherapy drugs work by destroying rapidly dividing cells, such as cancer cells. Oxaliplatin is administered intravenously while capecitabine is taken orally as tablets. ### Clinical Use XELOX has shown effectiveness as a first-line treatment for metastatic colorectal cancer, with response rates, time to progression, and overall survival similar to those observed with fluorouracil/leucovorin/oxaliplatin combinations. It provides a more convenient regimen that may be preferred by both patients and healthcare providers. ### Side Effects Common side effects include: - Sensory neuropathy (tingling or numbness in hands/feet) - Gastrointestinal issues (diarrhea, nausea) - Hand-foot syndrome - Fatigue The safety profile is predictable and similar to the FOLFOX4 regimen, except that myelosuppression (low blood counts) is less common with XELOX.

Other names

Sintilimab + RC48 + XELOXRC48/Sintilimab/XELOX